文献速递消化道肿瘤放疗放疗物理与技术

局部晚期胰腺癌碳离子放疗剂量学约束评估

Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer.
PubMed 文献 · Radiat Oncol · 2020-05-07

本研究为13例连续局部晚期胰腺癌患者生成碳离子放疗计划,比较4.6 GyRBE×12、4.0 GyRBE×14和3.0 GyRBE×17三种剂量分割方案对十二指肠、胃和小肠剂量约束的满足情况。结果显示,前两种方案仅在靶区未紧邻危及器官时可可靠达到关键高剂量约束,而3.0 GyRBE×17在所有病例中均可满足关键约束,但低剂量约束在任何方案下均无法统一达到。

要点

  • 4.6 GyRBE×12和4.0 GyRBE×14仅在靶区未紧邻危及器官时可可靠满足关键高剂量约束。
  • 3.0 GyRBE×17在所有病例中均可满足关键高剂量约束。
  • 任何剂量方案均无法统一满足低剂量约束。

核心结论

  • 部分局部晚期胰腺癌患者可安全接受4.6 GyRBE×12碳离子放疗,但更保守的3.0 GyRBE×17方案可能适用于更广泛人群。

研究设计与样本

  • 为13例连续未选择的局部晚期胰腺癌患者生成碳离子放疗计划,比较三种剂量分割方案。

主要发现

  • 使用4.6 GyRBE×12和4.0 GyRBE×14时,关键高剂量约束仅在靶区未紧邻危及器官时可可靠达到。
  • 使用3.0 GyRBE×17时,所有病例均可满足关键高剂量约束。
  • 任何剂量方案均无法统一满足低剂量约束。

关键数值与推荐

  • 评估的剂量分割方案为4.6 GyRBE×12、4.0 GyRBE×14和3.0 GyRBE×17。
  • 关键高剂量约束针对十二指肠、胃和小肠的已发表剂量约束。

临床怎么用

  • 对于肿瘤较大或紧邻胃肠道危及器官的局部晚期胰腺癌患者,可考虑采用3.0 GyRBE×17的保守碳离子放疗方案。
  • 该研究结果已用于指导一项正在进行的临床试验。

局限性

  • 本研究为剂量学分析,样本量较小(13例),未报告临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify a safe carbon ion radiotherapy (CIRT) regimen for patients with locally advanced pancreatic cancer (LAPC). METHODS: We generated treatment plans for 13 consecutive, unselected patients who were treated for LAPC with CIRT at our center using three dose and fractionation schedules: 4.6 GyRBE × 12, 4.0 GyRBE × 14, and 3.0 GyRBE × 17. We tested the ability to meet published dose constraints for the duodenum, stomach, and small bowel as a function of dose schedule and distance between the tumor and organs at risk. RESULTS: Using 4.6 GyRBE × 12 and 4.0 GyRBE × 14, critical (high-dose) constraints could only reliably be achieved when target volumes were not immediately adjacent to organs at risk. Critical constraints could be met in all cases using 3.0 GyRBE × 17. Low-dose constraints could not uniformly be achieved using any dose schedule. CONCLUSION: While selected patients with LAPC may be treated safely with a CIRT regimen of 4.6 GyRBE × 12, our dosimetric analyses indicate that a more conservative schedule of 3.0 GyRBE × 17 may be required to safely treat a broader population of LAPC patients, including those with large tumors and tumors that approach gastrointestinal organs at risk. The result of this work was used to guide an ongoing clinical trial.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lin LC, Jiang GL, Ohri N, et al. Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer. Radiat Oncol. 2020. PMID: 32381042. doi:10.1186/s13014-020-01515-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。